More than half of a group of severely ill COVID-19 patients improved after receiving an experimental antiviral drug, although there is no way to know the odds of that happening without the drug, because there was no comparison group, doctors said on Friday.
The results published in the New England Journal of Medicine are the first in COVID-19 patients for remdesivir.
The Gilead Sciences drug has shown promise against other coronaviruses in the past and in lab tests against the one causing COVID-19, which has claimed more than 100,000 lives.
No drugs have been approved for treating the disease. At least five large studies are testing remdesivir, and the company also has given it to more than 1,700 patients on a case-by-case emergency basis.
Friday’s results are on 53 of those patients, ages 23 to 82, hospitalized in the US, Europe, Canada and Japan. Thirty-four of them were sick enough to require breathing machines.
All were given the drug intravenously for 10 days or as long as they tolerated it.
After 18 days on average, 36 patients, or 68 percent, needed less oxygen or breathing machine support.
Eight others worsened. Seven patients died, nearly all of them older than 70.
The 13 percent mortality rate is lower than seen in some other reports, but no true comparisons can be made without a study rigorously testing the drug in similar groups of patients, the authors said.
A dozen patients had serious problems, but it was not clear whether they were from the drug or their disease. Those included septic shock and trouble with kidneys and other organs. Four discontinued treatment because of health problems they developed.
“It looks encouraging,” said Elizabeth Hohmann, an infectious disease specialist at Massachusetts General Hospital who is helping lead one of the studies testing the drug.
The problems that occurred were not unexpected given the disease, she said.
Derek Angus, critical care chief at the University of Pittsburgh Medical Center who was not involved with the research, said the recovery rate is good, but “there is no way of knowing from this series if remdesivir was helpful.”
“We cannot draw definitive conclusions from these data, but the observations from this group of hospitalized patients who received remdesivir are hopeful,” said lead author Jonathan Grein, director of hospital epidemiology at Cedars-Sinai Medical Center in Los Angeles, in a statement from Gilead.
The Foster City, California-based company provided the medication and also helped analyze the results.
Results from more rigorous studies are expected by the end of this month.
Additional reporting by Bloomberg
BLUE WAVE: The KMT’s Chiang Wan-an defeated the DPP’s Chen Shih-chung and is to become Taipei mayor, while President Tsai Ing-wen stepped down as DPP chairperson after many of the party’s candidates, handpicked by the leadership, performed poorly The Chinese Nationalist Party (KMT) yesterday flipped key mayoral seats in Taipei, Taoyuan and Keelung, and won control of 13 out of 22 cities and counties in the nine-in-one local elections. President Tsai Ing-wen (蔡英文) last night resigned as Democratic Progressive Party (DPP) chairperson over a poor showing by the party’s candidates, who were handpicked by the DPP leadership rather than chosen through primaries. The Taiwan People’s Party (TPP) won its first high-profile race with Hsinchu mayoral candidate Ann Kao (高虹安) defeating Shen Hui-hung (沈慧虹) of the DPP with 45.02 percent of the vote to Shen’s 35.68 percent. Voters were choosing more than
UNDETERRED: The US chip designer’s plan showed that Taiwan remains attractive for investment by global companies despite cross-strait tensions, Wang Mei-hua said US graphics chip designer Nvidia Corp is planning to relocate its Hong Kong-based logistics center to Taiwan, Minister of Economic Affairs Wang Mei-hua (王美花) said on Wednesday. The government had been in discussions with Nvidia regarding tax incentives to facilitate the move since last year, Wang said in an interview with the Central News Agency, adding that the two sides had reached a consensus. Wang did not provide details about the timetable for the move or the planned tax arrangements for Nvidia. The relocation would boost the local economy, as Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) is a major supplier of graphics processing
Kaohsiung police last week busted a money laundering operation suspected of seeking to interfere in tomorrow’s local elections. The operation was allegedly headed by a man surnamed Lee (李), who had received NT$9.5 billion (US$306.18 million) from China over the past six months, Kaohsiung police said yesterday, adding that Lee’s ring is suspected to be part of a larger Chinese effort to interfere in the elections and support pro-China candidates. Officers arrested Lee, 35, and his girlfriend, searched his mansion, and seized the money he had allegedly received from China and three luxury vehicles, police said. The operation was disguised as an online
CAUTION: Wearing a mask in crowded places and for people with chronic illnesses or allergies can help prevent COVID-19 and other infectious diseases, the CECC said The mask mandate for outdoor settings is to lifted on Thursday, and the weekly cap on international inbound travelers is to be removed on Dec. 10, the Central Epidemic Command Center (CECC) said at its regular news conference yesterday. The center also announced that starting from Friday, children aged five to 11 can receive a COVID-19 vaccine booster, and that rules for visiting hospital patients are to be partially eased from Dec. 10. While wearing a mask will no longer be mandatory outdoors, Deputy Minister of Health and Welfare Victor Wang (王必勝) reminded the public that it would still be required